Latest news with #UnitedStatesFood&DrugAdministration
Yahoo
5 days ago
- Health
- Yahoo
Crackers Sold at Target, Wegmans, and Other Retail Giants Recalled Due to Allergen Exposure
On June 4, the United States Food & Drug Administration (FDA) announced that Firehook is recalling one lot of its Classic Sea Salt Organic Crackers distributed across 11 states. The reason: They may contain sesame seeds, despite the label not disclosing that information. To be clear, this cracker flavor isn't supposed to contain sesame seeds. An investigation revealed that a temporary breakdown occurred in the company's production and packaging processes, resulting in incorrect labels being applied. It appears that one of Firehook's other staple flavors—which do contain sesame seeds—was accidentally sold under the Classic Sea Salt label. These flavors include: Multigrain Za'atar Crackers Everything Crackers Sesame is one of the nine most common food allergies in the nation, so if someone were to consume this product mistakenly, the side effects could be life-threatening. While the FDA announcement didn't reveal which retailers sold the affected item, we do know that Firehook Crackers are currently sold at the following major retailers: Wegmans Whole Foods As of June 5, no one has fallen ill from consuming the Name: Firehook Artisan Baked Classic Sea Salt Organic Crackers, 8 oz Date of Recall: May 30, 2025 UPC Code: 8 99055 00063 5 Best By Date: 09/29/25 Distribution: Connecticut, Massachusetts, Maryland, Maine, North Carolina, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, VirginiaIf you purchased the affected item, you're eligible for a full refund. You can return it to the retailer you purchased from, whether online or in person. If you have any other questions regarding the recall, you can contact Firehook at 1-888-580-0745 Monday through Friday, 8:00 a.m.-4:00 p.m. EST. Read the original article on SIMPLYRECIPES
Business Standard
26-05-2025
- Business
- Business Standard
Dr Reddys Labs' manufacturing facility gets two form 483 observations from US FDA
Dr Reddys Laboratories said that the United States Food & Drug Administration (US FDA), post a GMP inspection, has issued a Form 483 with 2 observations to the company's Telangana-based manufacturing facility. In a regulatory filing made on Saturday (24 May 2025), the company informed that the US FDA had conducted a GMP inspection at its API manufacturing facility in Miryalaguda, Telangana, India. The inspection was conducted from 19 May 2025 to 24 May 2025. Post the inspection, the American regulatory agency has issued a Form 483 with 2 observations. The pharmaceutical company stated that it would address the said observation from the US FDA within the stipulated timeline. Hyderabad-based Dr. Reddys Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. The company reported a consolidated net profit of Rs 1,594 crore for the quarter ended March 2025 (Q4FY25), marking a 22% year-on-year increase from Rs 1,307 crore in the same period last year. Revenue from operations rose 20% year-on-year to Rs 8,506 crore, compared to Rs 7,083 crore in Q4FY24. The scrip rose 0.46% to currently trade at Rs 1235.40 on the BSE.
Business Standard
17-05-2025
- Business
- Business Standard
USFDA completes GMP inspection of Dr Reddy's Middleburgh facility in New York
Dr Reddys Laboratories announced that the United States Food & Drug Administration (USFDA) completed a GMP inspection at its API Middleburgh facility in New York. The inspection was conducted from 12th May, 2025 to 16th May, 2025 (US EST time). The company has been issued a Form 483 with 2 observations.
